Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Alaunos Therapeutics ( (TCRT) ) is now available.
On June 24, 2025, Alaunos Therapeutics, Inc. entered into a Subscription Agreement to issue and sell Series A-2 Convertible Preferred Stock in a private offering, raising $850,000. The Series A-2 Preferred Stock, with a stated value of $1,000 per share, offers a 10% annual dividend and voting rights on an as-converted basis with common stock. This strategic move may enhance Alaunos Therapeutics’ financial flexibility and influence its market positioning.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 498,521
Technical Sentiment Signal: Sell
Current Market Cap: $7.39M
See more data about TCRT stock on TipRanks’ Stock Analysis page.